Records containing: Postmenopause

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

• CLINICAL_TRIALS study record update · 2008-12-12
  A Multi-Center, Open-Label, Non-Comparative Study Investigating the Efficacy and Tolerability of Angeliq® in Postmenopausal Thai Women With Vasomotor Symptoms Over Three 28-Day Treatment Cycles
• CLINICAL_TRIALS study record update · 2008-05-29
  A Phase II Long-Term Extension Safety Study of J867 Administered With Estrogen to Postmenopausal Women
• CLINICAL_TRIALS study record update · 2008-05-29
  A Phase II Pilot Study to Evaluate the Safety and Efficacy of J867 Administered With Estrogen to Postmenopausal Women
• CLINICAL_TRIALS study record update · 2008-03-12
  Endometrial Safety of a Low Dose Continuous Combined 17 -Estradiol/Dydrogesterone Hormone Replacement Regimen (E2 0.5 mg/ D 2.5 mg) in Postmenopausal Women - A One-Year, Open Label, Multi-Center Study
• CLINICAL_TRIALS study record update · 2008-03-12
  A Randomized, Placebo-Controlled, Double-Blind, Multi-National Study to Demonstrate Efficacy of Continuous Combined 0.5 mg Estradiol and 2.5 mg Dydrogesterone in the Treatment of Vasomotor Symptoms in Postmenopausal Women in Comparison to Placebo Over 3 Months, and to Investigate the Bleeding Pattern Over a Double-Blind Treatment Period of One Year Compared With Continuous Combined 1 mg Estradiol and 5 mg Dydrogesterone
• Organize your saved records without ads with Plus.
• CLINICAL_TRIALS study record update · 2008-03-04
  Biologic Activity of a Selective Progesterone Receptor Modulator, CDB-2914, in Post-Menopausal Women
• CLINICAL_TRIALS study record update · 2008-03-04
  Vascular and Metabolic Effects of Hormone Therapy Combined With L-Arginine in Postmenopausal Women
• CLINICAL_TRIALS study record update · 2008-03-04
  Immunomodulatory Effects of Hormone Therapy in Postmenopausal Women With Chronic Chlamydia Pneumoniae or Cytomegalovirus Infection
• CLINICAL_TRIALS study record update · 2008-01-16
  An Open-Label, Single-Dose, Randomized, 4-Period, Crossover, Bioequivalence Study of Clinical and Commercial Formulations of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women
• CLINICAL_TRIALS study record update · 2007-12-28
  A Multicenter, Double Blind, Randomized, Placebo Controlled Study to Assess the Safety and Efficacy of Bazedoxifene in Postmenopausal Asian Women
• CLINICAL_TRIALS study record update · 2007-12-28
  A Postmarketing Surveillance Study Evaluating the Tolerability and Safety of PREMARIN VAGINAL CREAM in Indian Postmenopausal Women
• CLINICAL_TRIALS study record update · 2007-12-28
  An Open Label, Randomized, Multicenter Study To Compare Bazedoxifene Steady-State Exposures Obtained With 2 Bazedoxifene Acetate/Conjugated Estrogen Formulations In Postmenopausal Women
• CLINICAL_TRIALS study record update · 2007-12-20
  A Prospective Open Label Study to Evaluate Vasomotor Symptoms Control and Bleeding Patterns With a Continuous Regimen of a New Progestin Trimegestone 0.125 mg and 17 b Estradiol 1 mg (Totelle),as HT on Postmenopausal Women
• CLINICAL_TRIALS study record update · 2007-12-06
  An Open-Label, Single-Dose, Randomized, 4-Period, Crossover, Bioequivalence Study of Three New Formulations of Premarin 0.45mg/Medroxyprogesterone Acetate (MPA) 1.5mg Compared With a Reference Formulation of Premarin/MPA (PremproTM) 0.45mg/1.5mg in Healthy Postmenopausal Women
• CLINICAL_TRIALS study record update · 2007-10-26
  Phytoestrogens and Cognition in Menopause
• CLINICAL_TRIALS study record update · 2007-06-11
  An Open-Label, Single-Dose, Randomized, 3-Period, Crossover, Bioequivalence Study Between Two New Formulations of 0.45 mg/1.5 mg Premarin / Medroxyprogesterone Acetate (MPA) Compared With a Reference Formulation of 0.45mg/1.5mg Premarin / MPA (Prempro™) in Healthy Postmenopausal Women.
• CLINICAL_TRIALS study record update · 2007-02-14
  Acute Effects of Estradiol on Lipolysis in Subcutaneous Adipose Tissue and Muscle Assessed by Microdialysis and Tissue Biopsies
• CLINICAL_TRIALS study record update · 2006-09-27
  An Open-Label, Single-Dose, Randomized, 4-Period, Partial Crossover Bioequivalence/Bioavailability Study Among Four New Formulations of Premarin 0.45 mg/Medroxyprogesterone Acetate (MPA) 1.5 mg Compared With a Reference Formulation of Premarin/MPA (Prempro) 0.45 mg/1.5 mg in Healthy Postmenopausal Women
• CLINICAL_TRIALS study record update · 2006-08-18
  Effects of Black Cohosh on Menopausal Hot Flashes